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Structural Basis for the Autoinhibition
of c-Abl Tyrosine Kinase
ments of c-Src except that c-Abl, like v-Src, lacks a
phosphorylation site corresponding to Tyr-527 (Superti-
Furga and Courtneidge, 1995). Nevertheless, the cata-
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The N-terminal half of the protein includes an N-terminal1Howard Hughes Medical Institute
“cap” of80 residues that is important for autoinhibitionDepartment of Molecular and Cell Biology
(Pluk et al., 2002) followed by an SH3 domain, an SH2Department of Chemistry
domain, and a tyrosine kinase domain (Figure 1A). WithUniversity of California, Berkeley
the exception of the N-terminal cap region, which is2 Physical Biosciences Division
unique to c-Abl and the Abl-paralog Arg (ABL2), theLawrence Berkeley National Laboratory
N-terminal half of c-Abl resembles closely the Src familyBerkeley, California 94720
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with the breakpoint cluster region (BCR) gene results in
the formation of a fusion protein, BCR-Abl, in which all
of c-Abl is preserved without mutation, except for aSummary
small N-terminal region, upstream of the SH3 domain
(Figure 1A). The fusion with BCR disrupts the internalc-Abl is normally regulated by an autoinhibitory mech-
control mechanism that keeps c-Abl in an inactive form,anism, the disruption of which leads to chronic my-
and the enhanced tyrosine kinase activity of the BCR-elogenous leukemia. The details of this mechanism
Abl protein results in the disease chronic myelogenoushave been elusive because c-Abl lacks a phosphotyro-
leukemia (CML) (for a recent review, see Sawyers, 2002).sine residue that triggers the assembly of the autoin-
The drug STI-571 is effective in the treatment of CMLhibited form of the closely related Src kinases by inter-
and blocks the kinase activity of BCR-Abl (Druker et al.,nally engaging the SH2 domain. Crystal structures of
1996; Sawyers, 2002). Crystal structures of the isolatedc-Abl show that the N-terminal myristoyl modification
kinase domain of Abl show that STI-571 displaces ATPof c-Abl 1b binds to the kinase domain and induces
and traps an inactive conformation of the kinase domainconformational changes that allow the SH2 and SH3
(Nagar et al., 2002; Schindler et al., 2000). Strikingly,domains to dock onto it. Autoinhibited c-Abl forms an
residues that interact with the drug are conserved in the
assembly that is strikingly similar to that of inactive
Src kinases, but STI-571 does not inhibit the kinase
Src kinases but with specific differences that explain
activity of c-Src (Druker et al., 1996; Schindler et al.,
the differential ability of the drug STI-571/Gleevec/im- 2000). A simple explanation for this phenomenon is that
atinib (STI-571) to inhibit the catalytic activity of Abl, Src is unable to adopt the particular conformation re-
but not that of c-Src. quired for the binding of STI-571 (Nagar et al., 2002).
However, Src and Abl are very closely related in se-
Introduction quence, and it is not clear why the distinct inactive con-
formations seen for their kinase domains cannot readily
The cellular form of the Abelson leukemia virus tyrosine interconvert. The origin of the differential sensitivity to-
kinase, c-Abl, is a relative of the Src family of tyrosine ward STI-571 is therefore not completely understood.
kinases. Its regulation has been a long standing enigma. Crystal structures of the Src kinases c-Src and Hck
c-Src, prominent in the history of cell signaling because have been determined in the inactive and assembled
of its relationship to the oncogene product v-Src, is states (Schindler et al., 1999; Xu et al., 1999) and that
controlled by an interaction between the Src homology of the kinase domain of the Src kinase Lck in the phos-
2 (SH2) domain of the protein and a phosphorylated phorylated active state (Yamaguchi and Hendrickson,
tyrosine residue (Tyr-527) in the C-terminal tail (Thomas 1996). The structure of the kinase domain of active Lck
and Brugge, 1997). v-Src lacks the Tyr-527 phosphoryla- resembles that of the active forms of other Ser/Thr and
tion site, and the catalytic activity of v-Src is unregu- tyrosine kinases (Huse and Kuriyan, 2002). Phosphoryla-
lated. c-Abl possesses all the essential regulatory ele- tion on Tyr-416 (chicken c-Src numbering) in the activa-
tion loop helps to maintain a conformation that allows
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sitioning catalytic residues for phosphate transfer. In-heidelberg.de (G.S.-F.)
7 These authors contributed equally to this work. activation of the Src kinases requires the internal en-
Cell
860
Figure 1. Structure of the c-Abl Kinase Domain
(A) Domain structure of c-Src, c-Abl 1b, and Bcr-Abl. Potential tyrosine phosphorylation sites are indicated with red circles and the residue
number. Additional phosphorylation sites in the C-terminal region of Abl following the kinase domain are not shown.
(B) Left, structure of the kinase domain of c-Abl bound to a myristoylated peptide (Structure A). Only the myristoyl group is shown, since the
rest of the peptide is disordered. Helices that change conformation upon myristoyl binding (I and I) are colored purple. A closeup view of
the myristoyl binding site is shown on the right. Superimposed and shown in gray is helix I from the structure of the isolated kinase domain
in the absence of the myristoyl group (PDB code 1M52).
(C) Molecular surface of Abl248–534 (Structure A) in the same orientation as in (B). Hydrophobic sidechains are colored green. A cutaway rendition
of the surface is shown on the right, rotated approximately 90 about the vertical axis with respect to the view on the left. Figures 1B–5 were
prepared using PyMOL (DeLano, 2002).
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gagement of the SH2 and SH3 domains to form the Results and Discussion
assembled state, triggered by the docking of the SH2
Structural Analysis of c-Abldomain to the phosphorylated tyrosine residue located
We initiated structural studies on a construct of humanin the C-terminal tail of the protein (Tyr-527 in the con-
Abl 1b, spanning residues 1–531, which we refer to asventional c-Src numbering).
c-Abl1–531. Expression of this construct in baculovirus-As with the Src kinases, the SH3 and SH2 domains
infected insect cells produced a protein that was myris-are both required for the proper regulation of c-Abl (Bar-
toylated but was extremely soluble, suggesting that theila and Superti-Furga, 1998; Franz et al., 1989; Jackson
myristoyl modification was probably not exposed to sol-and Baltimore, 1989; Muller et al., 1993), and it has been
vent. Further investigation showed that a short myristoy-suggested that c-Abl adopts an assembled structure
lated peptide interacts with the isolated catalytic domainsimilar to that of the Src kinases when inactive (Pluk et
of c-Abl with micromolar affinity (Hantschel et al., 2003al., 2002; Williams et al., 1997) despite the lack of a
[this issue of Cell]).residue corresponding to Tyr-527 of c-Src. It has been
We determined three crystal structures that have shedshown recently that the N-terminal half of c-Abl is suffi-
light on the regulatory mechanism of c-Abl (Table 1).cient for maintenance of the inactive state (Pluk et al.,
Two small molecule inhibitors of kinase activity, STI-5712002). In particular, the N-terminal cap region of c-Abl
and PD166326, proved helpful for crystallization, but weis essential for regulation, suggesting that the cap some-
do not discuss them in detail here since the essentialhow compensates for the lack of a Src-like C-terminal
features of their interaction with the kinase domain havephosphotyrosine. This has no precedent in the Src ki-
been described (Nagar et al., 2002; Wisniewski et al.,nases, where the corresponding N-terminal unique re-
2002). We first determined, at 1.75 A˚ resolution, thegion is crucial for membrane anchorage, but not for the
structure of the isolated kinase domain of c-Abl boundregulation of kinase activity (Koegl et al., 1995).
to STI-571 and to a myristoylated peptide correspondingThere are significant differences in the structures of
to the N-terminal 16 residues of Abl 1b (Structure A).the Src and Abl kinase domains despite close similarity
We also crystallized myristoylated c-Abl1–531 bound toat the sequence level (47% identity) (Nagar et al., 2002).
PD166326 and determined its structure at 3.4 A˚ resolu-The major inactivating switch within the kinase domain
tion (Structure B). Finally, we determined the structure
of c-Abl is a large conformational change at the base
of a construct of c-Abl spanning residues 46–534
of the activation loop, not seen in c-Src or Hck, which
(c-Abl46–534, beginning at the first exon that is common
flips the positions of aspartate and phenylalanine side
to the 1a and 1b spliceforms and continuing until the
chains in a conserved Asp-Phe-Gly (DFG) motif (resi- end of the kinase domain), to which we added PD166326
dues 400–402; Abl 1b numbering) (Nagar et al., 2002). and myristic acid during purification and crystallization,
The flipped conformation of the aspartate side chain respectively. This allowed the determination of the crys-
prevents the coordination of the catalytically important tal structure of an assembled, myristate bound form of
magnesium ion at the active site. This conformational c-Abl at 1.8 A˚ resolution (Structure C).
change in the DFG motif is inconsistent with a closure
of the kinase domain that is seen in inactive c-Src and
Myristoyl-Induced Conformational Changes
Hck, and the catalytic domain of c-Abl is essentially in the Kinase Domain
in the open conformations seen in active kinases. The The myristoyl group penetrates deep into the base of
binding of STI-571 requires this open conformation, as the C lobe of the kinase domain in Structure A (Figure
well as displacements in the DFG motif and the activa- 1B). When the myristoyl group is absent, the C-terminal
tion loop (Nagar et al., 2002). An important question is helix of the kinase domain, I, extends from residue
whether these distinctive conformational features of the Ser-504 to Ser-522, with subsequent residues being dis-
isolated Abl kinase domain persist in the assembled ordered (Nagar et al., 2002). In the presence of the myris-
state of the protein. toyl group, helix I breaks at residue Phe-516, with resi-
We now present crystallographic analyses of an au- dues Phe-516 to Ser-519 forming a four-residue turn,
toinhibited fragment of c-Abl 1b and show that it adopts which produces a 90 degree bend in the direction of
an assembled state, which is strikingly similar in general the polypeptide backbone before it forms another helix,
terms to that of the Src kinases, with the SH3 and SH2 I (Figure 1B). The new helix I consists of three turns,
domains docked onto the surface of the kinase domain spanning residues Ser-520 to Lys-531.
that is distal to the active site. The internal docking of The myristoyl group is bound in a deep pocket formed
the SH2 domain requires the induction of a sharp bend by hydrophobic side chains emanating from helices E
in the C-terminal helix at the base of the kinase domain. (Ala-356, Leu-359, Leu-360), F (Leu-448, Ala-452, Tyr-
This conformational change is triggered by the binding 454),H (Cys-483, Pro-484, Val-487, and aliphatic atoms
of the N-terminal myristoyl group of the protein to the of the Glu-481 side chain), and the new helix, I, (Ile-
base of the kinase domain, and the generation of this 521, Val-525, Leu-529) (Figure 1B). The inner portion of
interaction appears to be a primary role of the N-terminal the binding site is approximately 10 A˚ deep and provides
cap region. Critical differences between c-Src and c-Abl a snug fit for the terminal nine carbon atoms of the
in the way in which the SH2 domain docks onto the myristoyl group (C6 to C14) (Figure 1C). The remaining
kinase domain are reflected in differences in the confor- carbon atoms of the myristoyl group (C2 to C5) lie in
mations of their kinase domains, which provides an ex- the broader opening of the pocket where the side chains
planation for the ability of STI-571 to bind preferentially of Val-525 and Leu-529 from the induced helix I form
a hydrophobic shelf for the myristoyl group. Approxi-to c-Abl over c-Src.
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Table 1. Data Collection and Refinement Statistics
Structure A (Abl248–534)b Structure B (Abl1–531)c Structure C (Abl46–534)c
Data Collection
Beamline ESRF ID14.1 ALS 8.2.1 ALS 8.2.2
Resolution (A˚) 30–1.7 (1.8–1.7) 75–3.4 (3.52–3.4) 38–1.8 (1.86–1.8)
Measured reflections (#) 268488 105428 360273
Unique reflections (#) 61592 17250 50963
Data Redundancy 4.4 6.1 7.1
Data Completeness (%) 92.9 (75.8) 95.1 (91.4) 99.9 (100.0)
Rsym (%)a 9.0 (50.9) 8.1 (46.5) 5.7 (58.4)
I/sig I 9.4 (2.8) 19.7 (3.4) 29.6 (3.5)
Refinement
R factor/R freed 21.0/24.2 30.6/31.5 19.6/22.1
Free R test set size (#/%) 2886/5.0 1106/6.8 2966/6.0
Number of protein atoms 2329 6584 3613
Number of heterogen atoms 104 73 45
Number of solvent atoms 233 0 276
Rmsd bond lengths (A˚) 0.008 0.010 0.009
Rmsd bond angles () 1.4 1.6 1.5
Rmsd B factors (A˚2) (main chain/side chain) 1.39/1.97 3.45/5.53 1.53/2.35
a Rsym  |I  I|/ I, where I is the observed intensity of a reflection, and  I  is the average intensity obtained from multiple observations of
symmetry-related reflections.
b Data processed with XDS/XSCALE.
c Data processed with DENZO/Scalepack.
d For refinement, the high-resolution cutoff used for Structure A was 1.75 A˚ and the low-resolution cutoff used for Structure B was 30.0 A˚.
mately 500 A˚2 is buried between the protein and the The residues that make up the myristate binding site
in c-Abl are all strictly conserved in the Abl paralog Arg,myristoyl group. There is no electron density for the
peptide portion of the N-terminal segment, suggesting suggesting that the myristoyl group of Arg 1b may also
bind to the kinase domain. The general structure of thethat specific interactions between the kinase domain
and the first few residues of the N-terminal cap of Abl base of the kinase domain is conserved between Abl
and the Src kinases. However, several residues that line1b may be limited. This is consistent with the results of
mutations in the N-terminal cap of Abl 1b (Hantschel et the myristate binding site in c-Abl are replaced in c-Src
by bulkier residues, which block the binding site (e.g.,al., 2003).
The conformation of helix I has been determined in Ala-356, Ala-452, Gly-482, and Val-487 in c-Abl are re-
placed in c-Src by Leu, Thr, Glu, and Leu). This suggestsseveral crystallographically independent structures of
the isolated kinase domain of c-Abl in the myristoyl-free that the myristoyl group of Src is unlikely to interact with
the kinase domain.form (Nagar et al., 2002; Schindler et al., 2000). In each
case, the conformation of helix I is essentially the same
and corresponds to the unbent and extended conforma- Crystallographic Analysis of the Inactive
and Assembled Form of c-Abltion (Figure 1B) also seen in one of the two kinase do-
mains in the crystal structure of c-Abl1–531 from which Crystals of the myristoylated and unphosphorylated
c-Abl1–531 complexed to PD166326 are obtained readilythe myristoyl group had been displaced during crystalli-
zation (see below). The bent conformation of the C-ter- but diffract X-rays weakly (3.4 A˚). There are two mole-
cules of c-Abl in the asymmetric unit of these crystals,minal helix is now observed in four crystallographically
independent views: two in the structure of the isolated one of which corresponds to an inactive and assembled
form (Structure B). Unexpectedly, only the kinase andkinase domain complexed to the myristoylated peptide
(Structure A), one in the crystal structure of myristoy- SH2 domains of the second molecule could be localized
in electron density maps. The second kinase domainlated c-Abl1–531 (Structure B), and one in the structure of
c-Abl46–534, to which myristate was added in trans (Struc- shows no evidence for a bound myristoyl group, and
its C-terminal helix I is in the straight conformationture C). We conclude that the kinase domain of c-Abl
undergoes a well-defined transition in which the C-ter- corresponding to myristoyl-free c-Abl.
The SH2 domain of the second c-Abl molecule is lo-minal helix of the kinase domain switches conformations
such that helix I is either straight or sharply bent and cated on top of the kinase domain so that it interacts
closely with the upper surface of the  sheet in the Nthat the myristoyl group is capable of inducing and stabi-
lizing the bent conformation without the assistance of lobe. The significance of this unusual SH2-kinase do-
main interaction is not clear, and there is no electronthe SH2 and SH3 domains. Comparison with the struc-
ture of the kinase domain without myristate and bound density for the SH3 domain or for the linker connecting
the kinase domain to the SH2 domain. This second c-Ablto STI-571/Gleevec/imatinib or PD173955 (Nagar et al.,
2002) indicates that the presence of the small molecule assembly has very high temperature factors (200 A˚2 ),
and its structure cannot be refined or analyzed in detail.inhibitors is unlikely to influence the myristate binding
site, which is located 25 A˚ from the inhibitors. Mass spectrometric analysis of the protein samples
Structure of Autoinhibited c-Abl Tyrosine Kinase
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used for crystallization indicate that the protein is intact face than in c-Src. The total surface area buried at the
SH2-kinase interface is 920 A˚2 in c-Abl, compared toand completely myristoylated, and it is not clear why
this molecule is in a disassembled state. 500 A˚2 and 460 A˚2 in c-Src and Hck, respectively.
Interestingly, certain aspects of the structure of c-AblDespite the limited resolution of the X-ray data, we
were able to generate a reasonably accurate model for are more similar to corresponding elements in c-Src
than in the Src kinase Hck (Schindler et al., 1999; Xu etthe assembled c-Abl molecule by using the known struc-
tures of the SH3, SH2, and kinase domains (Nagar et al., 1999). When C atoms in the SH3-SH2 unit, the SH2-
kinase linker, and the N lobe are superimposed betweenal., 2002; Nam et al., 1996). As in c-Src, the linker con-
necting the SH2 domain to the kinase domain (SH2- c-Abl and Hck, 254 residues are aligned with a rms
deviation of 2.2 A˚, compared to 1.7 A˚ for the c-Srckinase linker) forms an internal binding site for the SH3
domain. The SH2 domain is docked onto the distal sur- alignment. Hck contains an intact Pro-x-x-Pro (PxxP,
where x is any residue) motif in the SH2-kinase linkerface of the kinase domain, which it approaches much
more closely than in c-Src or Hck. Despite the general (Figure 3A). The two proline residues pack against the
SH3 domain, and the SH2-kinase linker forms a nearlysimilarities between c-Abl and the Src kinases, the ki-
nase domain of c-Abl retains the conformation seen regular polyproline type II helix, the standard recognition
element for SH3 domains (Kuriyan and Cowburn, 1997).earlier in structures of the isolated and unphosphory-
lated kinase domains, which is distinctly different from The second proline residue of the PxxP motif is replaced
in c-Abl and c-Src by Tyr-245 and Gln-253, respectively.the conformation of the kinase domain in c-Src (Nagar
et al., 2002; Schindler et al., 2000). In c-Abl and c-Src the linker is distorted so that Tyr-245
(Figure 2A) and Gln-253 point away from the surface ofThere is no clearly interpretable electron density for
the80 residue N-terminal cap region for the assembled the SH3 domain, packing against the kinase domain
instead (Figure 3A). An interesting question is whetherc-Abl molecule, although there is some evidence for
localized interactions with the SH3-SH2 assembly. these structural differences are correlated with a signifi-
cant difference in the ease of activation of c-Src or c-AblStrong peaks in electron density maps, consistent with
the presence of unmodeled peptide segments, are seen by SH3 displacement when compared to Hck.
Tyr-245 is a site of regulatory control in c-Abl, within the vicinity of the N-terminal region of the SH3 domain
and also at the junction of the SH3 and SH2 domains phosphorylation of this residue potentiating catalytic
activity (Brasher and Van Etten, 2000). The distortionwith the SH2-kinase linker (indicated schematically in
Figure 4). The low resolution and disconnected nature of the SH2-kinase linker from ideal polyproline type II
geometry results in the packing of Tyr-245 in a hy-of these electron density features preclude a detailed
molecular analysis. Nevertheless, we conclude that lim- drophobic crevice formed by the side chains of Lys-313
and Pro-315 of the kinase domain. Clearly, phosphoryla-ited regions of the N-terminal cap, probably the function-
ally important residues Lys-70 and Leu-73 (Hantschel tion of Tyr-245 would dislodge it from this nonpolar site
and disrupt the assembled structure, consistent with theet al., 2003), interact with the SH2 and SH3 domains,
perhaps further strengthening the connections between high levels of activity observed upon phosphorylation of
Tyr-245 in c-Abl (Brasher and Van Etten, 2000).them and the kinase domain.
The assembled structure is consistent with a number
of mutations made in the SH3 domain of c-Abl. ForAnalysis of the Assembled c-Abl Structure
example, mutations in the “RT-loop” of the SH3 domainat 1.8 A˚ Resolution
(residues 91–99) do not result in the activation of c-AblThe crystal structure of c-Abl46–534, complexed to
(Brasher et al., 2001). This result is consistent with thePD166326 and myristate (added in trans) is very similar
lack of extensive contact between the SH2-kinase linkerto Structure B, except that it is resolved at high resolu-
and the RT-loop due to the replacement of the secondtion (Figure 2A). There is no electron density for the
proline of the PxxP motif in the SH2-kinase linker ofportion of the N-terminal cap included in this construct
c-Abl by Tyr-245 (Figure 3A). Glu-117 and Lys-313 have(residues 46–82), and the modeled structure begins at
been implicated in the autoinhibition of c-Abl activitythe first residue of the SH3 domain.
and predicted to form a salt bridge (Barila and Superti-There is particularly good agreement between c-Abl
Furga, 1998), and the structure confirms this interaction.and c-Src in the SH3-SH2 subassembly (Figure 2B).
Replacement of Ser-94 in c-Abl by arginine was shownLeast-squares superimposition of the SH3-SH2 unit, in-
to suppress activation relative to wild-type Abl (Brashercluding the SH3-2 connector, results in a root mean
et al., 2001), and this position is occupied in c-Src bysquare (rms) deviation in C atoms of 1.2 A˚ between
an arginine residue that interacts with carbonyl groupsc-Abl and c-Src for 151 structurally aligned residues. If
presented by the SH2-kinase linker, suggesting that thethe SH2-kinase linker and the N lobe are included in the
arginine in the S94R mutation in c-Abl might form similarstructural comparison, the rms deviation in C atoms is
interactions.1.7 A˚. This close structural correspondence between
c-Src and c-Abl does not extend to the C lobe of the
kinase domain, which is rotated outwards in c-Abl by Docking of the SH2 Domain Requires a Sharp
Bend in the C-Terminal Helix of the Kinaseabout 20, so that it approaches the SH2 domain more
closely. Given the preservation of the SH3-linker-N lobe Domain and Is Incompatible with SH2 Ligation
The coupling between the SH2 domain and the kinaseinterface, the opening up of the N lobe with respect to
the C lobe is correlated with a movement of the SH2 domain in both c-Src and Hck relies on the phosphory-
lated tyrosine residue in the C-terminal tail. In c-Abl, indomain of c-Abl toward the C-terminal lobe of the ki-
nase, resulting in a significantly tighter SH2-kinase inter- contrast, the SH2 domain is docked closely onto the
Cell
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Figure 2. Structure of Assembled c-Abl
(A) Ribbon and surface representations of c-Abl (Structure C).
(B) Superposition of the structure of c-Src (red; PDB code 2SRC) onto the SH3 and SH2 domains (residues 83–233) of Abl46–534 (Structure C;
green).
kinase domain through an interlocking network of hydro- I-I loop. Asn-154 makes a hydrogen bond with the back-
bone carbonyl group of Glu-513, an interaction that knitsgen bonding interactions (Figure 3B). These interactions
can only occur upon the restructuring of the C-terminal the domains together by positioning the Glu-513 side
chain appropriately for interaction with the SH2 domain.helix I, as induced here by myristate binding.
The carboxyl group of Glu-157 of the SH2 domain is A key set of interactions is made by Tyr-158 of the
SH2 domain, the aromatic ring of which stacks, almostlocated near the positive pole of the helix dipole of I,
the orientation of which is dependent on the presence perfectly, with that of Tyr-361 within helix E of the
kinase domain. The hydroxyl group of Tyr-158 forms aof myristate. Other interactions involve the packing of
the N-terminal helix of the SH2 domain, SH2-A, against hydrogen bond with the backbone carbonyl group of
Asn-393 of the kinase domain, which in turn forms ahelices E and I of the kinase domain. The side chains
that lie along the outer edge of SH2-A interact with hydrogen bond with Asn-240, located at the beginning
of the interaction between the SH2-kinase linker and thethe kinase domain through a series of direct hydrogen
bonding interactions. Ser-152, located at the N-terminal SH3 domain. The close juxtapositioning of the SH2 and
kinase domains in c-Abl therefore includes interactionsend of the helix, makes a hydrogen bond with Glu-513
of the kinase domain. Arg-153, a side chain that interacts that extend into the SH3-kinase interface, in a manner
not seen in the Src-kinases (Figure 3B).with the phosphotyrosine residue of target peptides,
makes two hydrogen bonds with the backbone carbonyl Without myristate, the C-terminal helix of the kinase
domain, I, extends out of the main body of the kinasegroups of residues 516 and 517 in the myristoyl-induced
Structure of Autoinhibited c-Abl Tyrosine Kinase
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Figure 3. SH3 and SH2 Interactions
(A) Surface rendition of the Abl SH3 domain of Abl46–534 (Structure C; yellow) bound to the SH2-kinase linker region (pink). The corresponding
SH2-kinase linker regions from c-Src (magenta) and Hck (green) are superimposed. Only the SH3 domain was used in the superimposition.
(B) SH2-kinase interface region of Abl46–534 (Structure C).
domain and the side chain of Phe-516, and subsequent formation of Arg-153 is not compatible with phosphotyr-
osine interaction. In addition, the I-I loop physicallyresidues of helix I occlude the SH2 docking site on the
kinase domain (Figure 4). This suggests that a gating blocks the binding site for the residues at the 1 and
2 positions of an SH2 bound phosphopeptide. Themechanism is at work within the kinase domain in which
the myristate plays a role in stabilizing the internal dock- peptide chain could not rearrange so as to avoid colli-
sion with the I-I loop while maintaining the interactionsing of the SH2 domain.
The orientation of the polypeptide backbone of phos- that hold the phosphotyrosine residue in place (Fig-
ure 5).phopeptides bound to SH2 domains is determined quite
precisely by hydrogen bonding interactions between the
SH2 domain and the backbone of the phosphopeptide Rigidity of the SH3-SH2 Assembly and Implications
for Catalytic Control(Kuriyan and Cowburn, 1997). Arg-153 in the SH2
domain is an important element in phosphopeptide rec- Given the close correspondence of the SH3-SH2 units of
c-Src and c-Abl, we looked to see whether the dynamicalognition, and in the assembled c-Abl structure, the con-
Cell
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Figure 4. SH2 Gating Mechanism
Ribbon and surface representation of Abl46–534
(Structure C) depicting the clash that occurs
between helix I in the myristoyl unbound
form and the SH2 domain. Helix I from the
structure of the isolated kinase domain in the
absence of myristoyl (PDB code 1M52) is col-
ored red and the new helices (I and I)
formed upon binding of myristate are colored
blue. Shown in shaded gray ellipses are re-
gions that contain isolated patches of un-
modeled electron density, potentially due to
residues from the N-terminal cap region.
properties of the SH3 and SH2 domains of assembled taneously, but as for our previous simulations of c-Src
and Hck, we have found the analysis of dynamical corre-c-Abl resemble that of c-Src and Hck. A total of four
molecular dynamics simulations were carried out to a lations in atomic positions to be informative (Young et
al., 2001). As before, we analyze the movements of Clength of 4 ns each. Two of these started from crystal
structures of assembled c-Abl and two from a variant atoms by reorienting each instantaneous structure in
the dynamical trajectory onto a single frame of referencestructure in which three residues in the SH3-2 connector
are replaced by glycine (S140G/L141G/E142G) (see Ex- and then calculating the standard correlation coefficient
between fluctuations in the positions of pairs of Cperimental Procedures). The first two (simulations one
and two) were initiated from the low-resolution structure atoms (Young et al., 2001). An analysis of the correlated
motions within the structure of assembled c-Abl revealsof the myristoylated c-Abl1–531 (Structure B), and the two
others (simulations three and four) were initiated from strong dynamic coupling between the motions in the N
lobe of the catalytic domain and the SH3 domain. Thisthe high-resolution structure of c-Abl46-534 (Structure C).
The assembled structures were stable over the simula- coupling extends into the SH2 domain via the SH3-2
connector. C atoms with cross correlation coefficientstion period of 4 ns, with rms deviations in C positions
of 1.5–2.0 A˚ from the refined high-resolution crystal of greater than 0.75 in simulation three are connected
with red lines in Figure 6A. These correlation coefficientsstructure of c-Abl46–534. The rms deviation in C positions
for the average structure from the simulation of c-Abl46–534 are calculated by using the C lobe of the kinase as a
frame of reference, which removes motions that areis 1.2 A˚ with respect to the crystal structure. The rms
deviation of the average structure of the c-Abl1-531 simula- highly correlated to those of the C lobe of the kinase.
For this reason, the SH2 domain appears unconnectedtion relative to the high-resolution crystal structure of
c-Abl46–534, which was obtained after the simulation was to the kinase domain in the illustrations in Figure 6.
Correlation coefficients calculated using the SH3 do-completed, is 1.5 A˚.
These simulations extend over too short a timescale main and the N lobe of the kinase as a frame of reference
reveal an extremely tight coupling between the SH2 do-for large-scale conformational transitions to occur spon-
Structure of Autoinhibited c-Abl Tyrosine Kinase
867
Figure 5. Blockage of Phosphorylated Peptide Binding
Ribbon and surface representation of Abl46–534 (Structure C), illustrating that the SH2 peptide binding site is partially occluded when docked
onto the kinase domain in assembled c-Abl. The tail peptide from Hck is shown bound to c-Abl using only the SH2 domains for superimposition.
main and the kinase domain (data not shown). Similar of NMR analyses of the isolated SH3-SH2 unit of c-Abl,
which have demonstrated that the domains are flexibleresults are obtained for simulation one.
relative to one another in solution (Fushman et al., 1999).The residues connecting the SH3 and SH2 domains
These apparently conflicting views of the SH3-SH2 unitin c-Abl adopt a strikingly similar structure to that seen
can be reconciled by considering our molecular dynam-in the Src-family kinases, stabilized by a network of
ics simulations of assembled c-Src and Hck (Young ethydrogen bonds. Results of a correlation analysis of
al., 2001), and of c-Abl, which suggest that the connectorsimulation four of assembled c-Abl with the glycine mu-
between the SH3 and SH2 domains forms an “inducibletations in the SH3-2 connector are shown in Figure 6B,
snap-lock,” adopting a rigid structure when the SH3calculated as for the simulation of the protein with the
and SH2 domains are internally liganded but becomingwild-type connector sequence. The turn conformation
flexible when these domains are released. The rigidityof the SH3-2 connector shows increased flexibility in
of the SH3-SH2 unit appears to be an essential compo-the simulation of this mutant variant of c-Abl. As a conse-
nent of the autoinhibitory mechanism, and the introduc-quence, there is a reduction in the correlation of the
tion of flexibility into the linker (by mutating three resi-motions of the SH2 and SH3 domains with the N lobe
dues to glycine) was shown to activate c-Src in vivoof the kinase domain and with each other. Similar results
(Young et al., 2001) (see Hantschel et al., 2003, for aare obtained in simulation two. As for c-Src and Hck,
mutational analysis of the SH3-2 connector in c-Abl).the introduction of glycine residues in the c-Abl SH3-2
The unexpected structural correspondence betweenconnector clearly breaks the rigidity of the assembly in
c-Abl and c-Src in the SH2-SH3 subassembly ratherthe simulations, predicting that c-Abl bearing the triple
than in the kinase domain helps explain the apparentlyglycine mutant will be active (Hantschel et al., 2003).
paradoxical selectivity of STI-571 for c-Abl over c-Src.
Our structural analysis shows that the formation of a
Conclusions structurally conserved and rigid SH2-SH3 clamp in these
The similarity between the SH3-SH2 assemblies in c-Abl two proteins results in the kinase domain adjusting its
and c-Src contrasts with the differences in the confor- conformation so as to accommodate the distinct mech-
mations of the kinase domains in the inactive states of anisms of SH2-kinase domain docking. Thus, c-Abl has
these proteins. In both c-Src and c-Abl, inactivation is its kinase domain in an open conformation with the DFG
coupled with “in/out” conformational transitions deep motif in the activation loop flipped, while c-Src does
within the mouth of the kinase domain. These transitions not. These distinctive features of the inactive kinase
are different in the Src kinases, where it involves helix domain have been shown previously to be required for
C, and c-Abl, where the DFG motif in the activation STI-571 binding (Nagar et al., 2002; Schindler et al.,
loop is flipped, but in both cases the transition from 2000), and our new results link them to the mechanism
inactive to active would require the mouth of the kinase of autoinhibition by the SH2 and SH3 domains. Our
domain to open or flex. A plausible mechanism for the structures of assembled and inactive Abl are consistent
action of the SH2 and SH3 domains is that by forming with the results of an in vitro screen for STI-571-resistant
a rigid clamp they prevent or dampen such breathing mutants of BCR-Abl, which revealed that the cap and
movements of the kinase domain (Williams et al., 1997; SH3 and SH2 domains are important for the recognition
Young et al., 2001). of STI-571 (Azam et al., 2003 [this issue of Cell]).
The discovery of a myristoyl-triggered conformationalRigidity in the SH3-SH2 unit contrasts with the results
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Figure 6. Schematic Diagram Indicating the
Most Strongly Correlated Pairs of C Atoms
in c-Abl46–534 (Structure C) Computed from Mo-
lecular Dynamics Simulations
A dynamic cross correlation matrix was com-
puted after superimposing each structure on
the C lobe of the kinase domain. Data were
computed over the 3.5 ns time period be-
tween 0.5 and 4.0 ns. Red lines connect C
atoms in the structure which have cross-cor-
relation coefficients of greater than 0.75. (A)
Correlation coefficients from a simulation of
the wild-type protein. (B) Cross correlations
for a simulation of a S140G/L141G/E142G tri-
ple mutant of c-Abl. Data were analyzed over
the same 0.5 ns to 4.0 ns time period. Both
simulations were initiated from the high reso-
lution structure of c-Abl (Structure C).
switch in the kinase domain was completely unex- ability of polypeptide backbones of N- or C-terminal
helical segments, tethered only at one end, to reorganizepected. One example of a soluble and myristoylated
protein kinase of known three-dimensional structure is drastically without affecting the structural core of the
protein. Although helix I is not located in the C-terminalthe cAMP dependent protein kinase PKA, where the
regulatory RII subunit switches the N-terminal myristoyl region of full-length c-Abl, we expect that the linker
connecting the kinase domain to the region encoded bymodification of the catalytic domain from a kinase-
bound state to a form that is released for interaction the last exon is flexible, allowing helix I to change
direction upon binding the myristoyl group.with membranes (Gangal et al., 1999). The myristoyl
group is bound in a hydrophobic pocket located be- It was known previously that mutations in the SH3
domain activate c-Abl, suggesting that SH3 displace-tween the unique N-terminal helix of PKA and the two
lobes of the kinase domain, and the details of the recog- ment by peptide ligands might be one mode of activa-
tion, as for the Src kinases (Barila and Superti-Furga,nition of the myristoyl modification appear to be unre-
lated to that seen in c-Abl. 1998). The crystal structure of c-Abl shows that the for-
mation of a phosphopeptide-SH2 complex would dis-The myristoyl-induced conformational change in
c-Abl is reminiscent of the structural changes induced lodge the SH2 domain from its docking site on the kinase
domain. As shown in Hantschel et al. (2003), phospho-in steroid/nuclear hormone receptors by the binding of
agonists. In these receptors, C-terminal  helices reor- peptides can activate c-Abl by SH2 displacement. Thus,
both c-Abl and the Src kinases may share a commonganize from a more or less straight conformation in the
unliganded receptor to one in which the polypeptide mode of activation by displacement of their peptide
binding modules.chain bends sharply and forms one face of the ligand
binding pocket (Renaud et al., 1995). The common ele- Our crystallographic analyses, focused on the Abl 1b
isoform, have revealed a role for the myristoyl group inment in c-Abl, PKA, and the hormone receptors is the
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-mercaptoethanol. The protein was eluted with a linear imidazolehelping to stabilize the assembled and inactive form of
gradient (20–500 mM), and fractions containing Abl were pooled.c-Abl. The alternative spliceform Abl 1a is not myristoy-
The protein was incubated with calf-intestinal alkaline phospha-lated but is regulated normally (O.H. and G.S.-F., unpub-
tase (CiP, Roche) overnight at 20C (5 U/mg recombinant protein),
lished data), suggesting that Abl 1a contains additional because 80% of the protein was phosphorylated (presumably on
interaction elements that compensate for the lack of the Ser or Thr) as determined by mass spectrometry and native PAGE.
A second Ni-column was used to remove the CiP. Abl-containingmyristoyl group. The very N-terminal region of Abl 1a
fractions were pooled and incubated with Tobacco Etch Virus prote-contains hydrophobic residues that are absent in Abl
ase overnight at 4C in order to cleave the hexa-histidine tag from1b, and one possibility is that these residues help induce
Abl. Next, inhibitor compound (PD166326) dissolved in DMSO wasthe bend in helix I that is essential for SH2 docking.
added atthree times the molar protein concentration with constant
Interactions that help pin the SH2 domain to the C lobe stirring at 20C. The inhibitor-protein complex was concentrated
of the kinase, an essential aspect of the autoinhibitory and loaded onto a Sephadex 200 gel filtration column (HiLoad 16/
60, Pharmacia) equilibrated in 20 mM Tris/HCl (pH 8.0), 100 mMmechanism, may also involve segments of the C-ter-
NaCl, and 5 mM DTT. Abl:inhibitor complex-containing fractionsminal region of full-length c-Abl that are known to play
were pooled and diluted 1:4 to reduce the salt concentration, loadeda role in regulation (Goga et al., 1993; Woodring et al.,
onto a 1 ml Resource Q column (Pharmacia) and eluted with a2001).
linear salt gradient (20–250 mM NaCl). The major peak was pooled,
The comparisons between c-Src and c-Abl now made concentrated to35 mg/ml and supplemented with 2–3 mM Triscar-
possible by our crystal structures draws attention to boxyethyl phosphine. For Abl46–534, myristic acid was added in a
ten-fold excess before concentrating. For Abl248–534, myristoylatedthe remarkable plasticity of the protein kinase domain,
peptide was added in 1.5-fold excess before concentrating to 20which is the only segment of the assembled and inactive
mg/ml. The peptide sequence is Myr-GQQPGKVLGDQRRPSL andstates of these protein kinases that is seen to adapt its
was synthesized at the Central Peptide Synthesis Unit of the Germanstructure to the differing requirements of the autoinhibi-
Cancer Research Centre in Heidelberg.
tory mechanisms. This emphasizes once more the op-
portunities that exist for developing small molecules Synthesis of STI-571 and PD166326
that inhibit protein kinases specifically by exploiting the STI-571 and PD166326 were synthesized and purified as described
(Kraker et al., 2000; Zimmermann et al., 1997). The compounds werediversity of regulatory mechanisms that control protein
dissolved and stored as 20 mM aliquots in DMSO at 80C untilkinase action.
needed.
Experimental Procedures
Crystallization and Data Collection
Using the hanging drop vapor diffusion method (0.6 l proteinProtein Expression and Purification
solution	 0.6 l reservoir solution), crystals of the Abl1–531 (constructThree different constructs of Abl were expressed: construct one
one) grew in 0.8 M ammonium tartrate at 20C (space group C2221(human c-Abl, spliceform 1b) encompasses the N-terminal 531 resi-
with a  112.9 A˚, b  147.4 A˚, c  153.4 A˚ and two molecules indues, including the myristoylation site, and is referred to as Abl1–531.
the asymmetric unit). Crystals of Abl46–534 (construct two) grew inConstruct two (mouse c-Abl) begins at the first common exon and
20% (w/v) PEG 3350, 200 mM potassium nitrate at 20C (spaceextends to residue 534 and is referred to as Abl46–534. There are only
group C2221 with a  118.3 A˚, b  123.9 A˚, c  74.8 A˚ and onetwo differences within the sequence spanning the structural model
molecule in the asymmetric unit). Crystals of Abl248–534 (construct(residues 83–531) between human and mouse c-Abl, Val-244 (hu-
three) grew in 22% (w/v) PEG 4000, 100 mM MES (pH 5.6), and 200man) to Ile (mouse) located in the SH2-kinase linker, and Asn-355
mM magnesium chloride at 4C (space group P1 with a  41.8 A˚,(human) to Ser (mouse) located on the surface of the C lobe of the
b  63.5 A˚, c  64.1 A˚ and two molecules in the asymmetric unit).kinase domain. Neither site is implicated in the regulatory mecha-
All crystals were cryoprotected with the addition of 25% glycerolnisms described here. Construct three (mouse c-Abl) is of the iso-
(v/v) and X-ray diffraction data were collected on crystals flash fro-lated kinase domain (residues 248–534, spliceform IV numbering)
zen in liquid nitrogen (Structure A) or initially frozen in liquid propaneand was expressed and purified as described previously (Nagar et
and stored in liquid nitrogen (Structures B and C) (Table 1). Dataal., 2002; Schindler et al., 2000), and is referred to as Abl248–534. Con-
for Abl1–531 and Abl46–534 were integrated and scaled with DENZO andstruct one was cloned into pFastBac1 (Gibco BRL) with a C-terminal
Scalepack (Otwinowski and Minor, 1997). Data for Abl248–534 werecleavage site for the Tobacco Etch Virus protease and a hexa-
processed with XDS (Kabsch, 1993).histidine tag introduced by PCR. Construct two was cloned into a
plasmid in which an N-terminal hexa-histidine tag is fused to the
Structure Determination and Refinementprotein (pFastbac HTa, Gibco BRL).
All of the structures were solved with molecular replacement usingTo minimize heterogeneity due to autophosphorylation the cata-
AMoRe (Navaza, 1994). The search models used for Abl1–531 (Struc-lytic domain in constructs one and two was rendered inactive by
ture B) and Abl46–534 (Structure C) were PDB entries 2ABL (SH2, SH3mutating the catalytic base Asp-382 to asparagine. Recombinant
domains) (Nam et al., 1996) and 1M52 (kinase domain) (Nagar et al.,bacmid DNA containing the Abl insert was prepared according to the
2002). The search model for Abl248–534 (Structure A) was PDB entrymanufacturer’s instructions (Bac-to-Bac expression system, Gibco
1IEP (Nagar et al., 2002). All models were subsequently refined withBRL) and transfected into Sf9 cells. Baculovirus obtained from the
the programs CNS (Brunger et al., 1998) and O (Jones et al., 1991)transfection was then used to infect Sf9 cells grown in suspension
(Table 1). After the refinement of Abl46–534 was completed, this modelto a density of 2.5 
 106 cells per ml at a multiplicity of infection of
was used to complete the analysis of Abl1–531. The refined Abl46–534ten. Cells were grown for 48 hr, centrifuged, resuspended in buffer
model was superimposed on the molecular replacement solutionA (50 mM Tris/HCl [pH 8.0], 10% glycerol, 15 mM -mercaptoetha-
for the assembled molecule of Abl1–531, and the positions of individualnol, and inhibitor cocktail pill [Roche]), flash frozen in liquid nitrogen,
domains were optimized by rigid-body refinement. For the disas-and stored at 80C. Western blots with anti-phosphotyrosine anti-
sembled molecule, the kinase domain and SH2 domain of Abl46–534body revealed that the protein was not tyrosine phosphorylated.
were individually superimposed on the molecular replacement solu-For a typical protein preparation, 4 liters of cells were thawed,
tion, followed by rigid-body refinement and application of an overalllysed by sonication, and centrifuged at 17,000 rpm for 1 hr. The
B factor to each domain.supernatant was filtered and loaded onto a 65 ml Q-Sepharose ion-
exchange column equilibrated in buffer A. Protein was eluted from
the column with 1 M NaCl. The total eluate was pooled and loaded Molecular Dynamics Simulations
Molecular dynamics simulations were carried out as described pre-onto a Ni-NTA column (Qiagen) equilibrated in 20 mM Tris/HCl [pH
8.0], 500 mM NaCl, 5% glycerol, 20 mM imidazole, and 5 mM viously for c-Src and Hck (Young et al., 2001). Simulations of the
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assembled Abl included residues 83–531, PD166326, and the myris- Ferguson, D.M., Spellmeyer, D.C., Fox, T., Caldwell, J.W., and Koll-
man, P.A. (1995). A second generation force field for the simulationtoyl group. Two simulations (one and two) were carried out starting
from the 3.4 A˚ structure of Abl1–531 bound to PD166326 (Structure of proteins, nucleic acids, and organic molecules. J. Am. Chem.
Soc. 117, 5179–5197.B). Simulation two incorporated mutations in the SH3-2 connector.
A second set of simulations (three and four) were carried out as DeLano, W.L. (2002). The PyMOL User’s Manual (San Carlos, CA:
before, except that the higher resolution structure (Structure C) was Delano Scientific).
utilized as the starting conformation, and Asp-400 was simulated
Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M.,
in a protonated (charge neutral) state. Asp-400 was determined to
Fanning, S., Zimmermann, J., and Lydon, N.B. (1996). Effects of a
be in a protonated state based on the geometry of this sidechain
selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-
in the high resolution structure and a comparison of this side chain
Abl positive cells. Nat. Med. 2, 561–566.
orientation with the orientations sampled within the original two
Franz, W.M., Berger, P., and Wang, J.Y. (1989). Deletion of ansimulations, where it existed in a 1 charge state. AMBER parm99
N-terminal regulatory domain of the c-abl tyrosine kinase activatesforce field parameters were utilized for the protein (Cornell et al.,
its oncogenic potential. EMBO J. 8, 137–147.1995). Parameters for the PD166326 inhibitor and the myristoyl
group were generated using the Antechamber module in Amber Fushman, D., Xu, R., and Cowburn, D. (1999). Direct determination
version 7.0. Charges for these two molecules were assigned con- of changes of interdomain orientation on ligation: use of the orienta-
forming to the BCC charge model using AM1 optimized geometries tional dependence of 15N NMR relaxation in Abl SH(32). Biochemis-
and potentials calculated in Mopac version 5.09mn. try 38, 10225–10230.
A truncated octahedral geometry constructed of water extending Gangal, M., Clifford, T., Deich, J., Cheng, X., Taylor, S.S., and John-
a minimum of 10 A˚ beyond the protein was used for periodic bound- son, D.A. (1999). Mobilization of the A-kinase N-myristate through
ary conditions. The net charge on the system was neutralized by an isoform-specific intermolecular switch. Proc. Natl. Acad. Sci.
the addition of 9 K	 ions, and an additional 34 K	/Cl ion pairs were USA 96, 12394–12399.
added to the system to model an approximate 150 mM ionic strength
Goga, A., McLaughlin, J., Pendergast, A.M., Parmar, K., Muller, A.,environment. The simulation of the SH3-SH2 connector mutant was
Rosenberg, N., and Witte, O.N. (1993). Oncogenic activation ofset up and carried out in an identical fashion, after manually intro-
c-ABL by mutation within its last exon. Mol. Cell. Biol. 13, 4967–4975.ducing the following mutations: S140G/L141G/E142G. The simula-
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K.,tions were carried out using the Sander module of Amber 7.0, using
Kuriyan, J., and Superti-Furga, G. (2003). A myristoyl/phosphotyro-16 processors on an IBM SP3 supercomputer located at the National
sine switch regulates c-Abl. Cell 112, this issue, 845–857.Energy Research Scientific Computing Center (NERSC).
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